Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($0.52), $0.01 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance